new formulations of Actonel and Fosamax and a new bisphosphonate called Reclast

View the FDA's preliminary statement concerning bisphosphonates and atrial fibrillation

Drug companies will promote new formulations of Actonel and Fosamax and a new bisphosphonate called Reclast.

It's a competitive market. There are a huge number of potential patients...and many dollars at stake.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote